Barclays Portfolio holdings
Barclays PLC, founded in 1690 by goldsmith bankers in London, is a British multinational financial institution headquartered in London, operating as one of the world’s oldest banks with a significant presence in investment banking, retail banking, and wealth management. Managing billions in assets, Barclays serves millions of customers globally through its retail arm (notably in the UK) and its investment banking division, which excels in trading, mergers and acquisitions, and capital markets, competing with Wall Street giants. The bank has navigated challenges like the 2008 financial crisis—opting for private funding over a government bailout—and has since focused on restructuring, digital innovation, and sustainable finance initiatives. With a rich history and a modern global footprint, Barclays remains a key player in both UK and international financial markets.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Gilead Sciences
GILD
|
+$479M |
| 2 |
Meta Platforms (Facebook)
META
|
+$465M |
| 3 |
State Street Consumer Discretionary Select Sector SPDR ETF
XLY
|
+$445M |
| 4 |
Kenvue
KVUE
|
+$434M |
| 5 |
Micron Technology
MU
|
+$431M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
NVIDIA
NVDA
|
+$3.24B |
| 2 |
Apple
AAPL
|
+$1.9B |
| 3 |
Microsoft
MSFT
|
+$1.56B |
| 4 |
PepsiCo
PEP
|
+$1.34B |
| 5 |
JPMorgan Chase
JPM
|
+$1.34B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Miscellaneous | 43.54% |
| 2 | Technology | 19.7% |
| 3 | Financials | 7.47% |
| 4 | Consumer Discretionary | 6.7% |
| 5 | Communication Services | 6.02% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
4426
Gyre Therapeutics
GYRE
$754M
| $131K | ﹤0.01% |
18,531
+5,135
| +38% | +$39.6K |
2024 Q2
6 quarters
|
|
|
PDS
4427
Precision Drilling
PDS
$1.07B
| $130K | ﹤0.01% |
1,813
+1,803
| +18,030% | +$111K |
2022 Q3
13 quarters
|
|
4428
Advantage Solutions
ADV
$354M
| $129K | ﹤0.01% |
5,873
+563
| +11% | +$16.3K |
2022 Q1
15 quarters
|
|
|
PONY
4429
Pony AI Inc
PONY
$2.64B
| $128K | ﹤0.01% |
8,809
-269,905
| -97% | -$4.49M |
2025 Q2
2 quarters
|
|
4430
AudioEye
AEYE
$87M
| $128K | ﹤0.01% |
12,785
+1,015
| +9% | +$13.1K |
2024 Q2
6 quarters
|
|
|
AISP
4431
Airship AI Holdings
AISP
$73M
| $128K | ﹤0.01% |
44,188
+16,024
| +57% | +$66K |
2024 Q2
6 quarters
|
|
4432
Cartesian Therapeutics
RNAC
$223M
| $127K | ﹤0.01% |
17,651
-191
| -1% | -$1.54K |
2019 Q4
24 quarters
|
|
|
AIRO
4433
AIRO Group Holdings
AIRO
$208M
| $127K | ﹤0.01% |
15,520
+5,652
| +57% | +$72.9K |
2025 Q2
2 quarters
|
|
4434
AllianzIM U.S. Equity Buffer10 Aug ETF
AUGT
$35.4M
| $127K | ﹤0.01% |
3,558
-693
| -16% | -$24.4K |
2025 Q1
3 quarters
|
|
4435
Pro-Dex
PDEX
$205M
| $126K | ﹤0.01% |
3,283
+175
| +6% | +$6.05K |
2025 Q2
2 quarters
|
|
4436
Invesco DB Base Metals Fund
DBB
$360M
| $126K | ﹤0.01% |
+5,505
| New | +$120K |
2025 Q4
0 quarters
|
|
4437
Cemex
CX
$13.8B
| $126K | ﹤0.01% |
10,961
+6,017
| +122% | +$62.2K |
2022 Q1
15 quarters
|
|
4438
FT Vest US Equity Enhance & Moderate Buffer ETF December
XDEC
$202M
| $125K | ﹤0.01% |
3,065
-1,943
| -39% | -$78.6K |
2024 Q3
5 quarters
|
|
4439
PUT
Charter Communications
CHTR
$12.5B
| $125K | ﹤0.01% |
600
-39,000
| -98% | -$8.77M |
2024 Q3
5 quarters
|
|
4440
Future Fuel
FF
$226M
| $125K | ﹤0.01% |
39,231
+3,815
| +11% | +$13.7K |
2016 Q3
37 quarters
|
|
4441
NET Power
NPWR
$123M
| $125K | ﹤0.01% |
54,750
+6,970
| +15% | +$21.8K |
2023 Q4
8 quarters
|
|
4442
Waldencast
WALD
$112M
| $125K | ﹤0.01% |
66,337
+6,587
| +11% | +$13.4K |
2022 Q3
13 quarters
|
|
4443
AllianzIM U.S. Equity 6 Month Buffer10 Feb/Aug ETF
SIXF
$52.2M
| $124K | ﹤0.01% |
3,895
-575
| -13% | -$18.1K |
2025 Q1
3 quarters
|
|
4444
CALL
Keros Therapeutics
KROS
$225M
| $124K | ﹤0.01% |
+6,100
| New | +$107K |
2025 Q4
0 quarters
|
|
4445
DocGo
DCGO
$36.6M
| $123K | ﹤0.01% |
139,891
+11,724
| +9% | +$12.5K |
2022 Q1
15 quarters
|
|
|
AVBH
4446
Avidbank Holdings
AVBH
$343M
| $123K | ﹤0.01% |
+4,623
| New | +$120K |
2025 Q4
0 quarters
|
|
4447
POSCO
PKX
$17.4B
| $122K | ﹤0.01% |
2,302
+1,201
| +109% | +$63.3K |
2025 Q2
2 quarters
|
|
|
MPX
4448
DELISTED
Marine Products Corp
MPX
| $121K | ﹤0.01% |
13,819
+1,316
| +11% | +$11.4K |
2019 Q1
27 quarters
|
|
4449
CareCloud
CCLD
$85.8M
| $121K | ﹤0.01% |
+41,412
| New | +$131K |
2025 Q4
0 quarters
|
|
4450
Duluth Holdings
DLTH
$149M
| $121K | ﹤0.01% |
58,043
+14,136
| +32% | +$41.8K |
2015 Q4
40 quarters
|
|
Similar funds
Barclays's Q4 2025 Portfolio in Review
As of Q4 2025, Barclays held 5,847 positions worth $417B, down 9.7% from $461B the previous quarter. Its ten largest holdings account for 35% of the portfolio.
Barclays withdrew a net $23.5B in Q4 2025, closing 641 positions and reducing 1,714 holdings. Its most notable exit was Verona Pharma, an estimated $149M position sold in full.
By sector, the portfolio is most concentrated in Miscellaneous at 44% of assets, down from 44% a quarter earlier, followed by Technology and Financials.
Against the trend, Barclays opened a new position in The Magnum Ice Cream Company N.V. worth $156M.
- Barclays's largest Q4 2025 buy was The Magnum Ice Cream Company N.V.: 9,862,859 shares worth $156M.
- Barclays added most to Gilead Sciences in Q4 2025, an estimated $479M increase.
- Barclays's biggest Q4 2025 reduction was NVIDIA, cutting an estimated $3.24B.
- Barclays fully exited Verona Pharma in Q4 2025, selling an estimated $149M.
- Barclays's ten largest holdings make up 35% of its $417B portfolio in Q4 2025.
- Barclays opened 403 new positions and closed 641 in Q4 2025.
- Barclays's portfolio value fell 9.7% quarter-over-quarter to $417B.
Based on Barclays's 13F filing for Q4 2025, filed 13 Feb 2026.